RabMAb

Anti-Survivin antibody [EP2880Y] (DyLight® 488) (ab139847)

Overview

  • Product nameAnti-Survivin antibody [EP2880Y] (DyLight® 488)See all Survivin primary antibodies ...
  • Description
    Rabbit monoclonal [EP2880Y] to Survivin (DyLight® 488)
  • ConjugationDyLight® 488. Ex: 493nm, Em: 518nm
  • Tested applicationsICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide against a region within the N-terminus of the Human Survivin protein (O15392).

  • Positive control
    • ICC: Hela cells.
  • General notes

    Produced under U.S. Patent No. 5,675,063.

Properties

Applications

Our Abpromise guarantee covers the use of ab139847 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/50 - 1/100.

Target

  • FunctionComponent of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May play a role in neoplasia. May counteract a default induction of apoptosis in G2/M phase. Inhibitor of caspase-3 and caspase-7. Isoform 2 and isoform 3 do not appear to play vital roles in mitosis. Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform.
  • Tissue specificityExpressed only in fetal kidney and liver, and to lesser extent, lung and brain. Abundantly expressed in adenocarcinoma (lung, pancreas, colon, breast, and prostate) and in high-grade lymphomas. Also expressed in various renal cell carcinoma cell lines.
  • Sequence similaritiesBelongs to the IAP family.
    Contains 1 BIR repeat.
  • Developmental stageExpression is cell cycle-dependent and peaks at mitosis.
  • DomainThe BIR repeat is necessary and sufficient for HBXIP binding.
  • Post-translational
    modifications
    Ubiquitination is required for centrosomal targeting.
    In vitro phosphorylation at Thr-117 by AURKB/STK12 prevents interaction with INCENP and localization to mitotic chromosomes.
  • Cellular localizationCytoplasm. Nucleus. Chromosome. Chromosome > centromere. Cytoplasm > cytoskeleton > spindle. Localizes on chromosome arms and inner centromeres from prophase through metaphase and then transferring to the spindle midzone and midbody from anaphase through cytokinesis. Colocalizes with AURKB at mitotic chromosomes.
  • Information by UniProt
  • Database links
  • Alternative names
    • API4 antibody
    • Apoptosis inhibitor 4 antibody
    • Apoptosis inhibitor survivin antibody
    • Apoptosis inhibitor4 antibody
    • Baculoviral IAP repeat containing 5 antibody
    • Baculoviral IAP repeat containing protein 5 antibody
    • Baculoviral IAP repeat-containing protein 5 antibody
    • BIRC 5 antibody
    • BIRC5 antibody
    • BIRC5_HUMAN antibody
    • EPR 1 antibody
    • IAP4 antibody
    • Survivin variant 3 alpha antibody
    • SVV antibody
    • TIAP antibody
    see all

Anti-Survivin antibody [EP2880Y] (DyLight® 488) images

  • Immunofluorescence analysis of HeLa cells labelling Survivin with ab139847 at 1/50 in green (left Panel) and DAPI in blue (right panel).

References for Anti-Survivin antibody [EP2880Y] (DyLight® 488) (ab139847)

ab139847 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab139847.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"